Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ISO IsoPlexis
1.280+0.020+1.59%
Close
01/27 16:00 ET
1.2800.0000.00%
Post Mkt Price 01/27 16:00 ET
High
1.320
Open
1.260
Turnover
33.99K
Low
1.240
Pre Close
1.260
Volume
26.45K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
IsoEnergy Brief: Appointing Darryl Clark as Vice President, Exploration
06:01 AM EST, 01/27/2023 (MT Newswires) -- IsoEnergy Brief: Appointing Darryl Clark as Vice President, Exploration
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LPTX, DCT, AQUA, ISO
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties
Moore Kuehn Encourages AQUA, DCT, ISO, and MAXAR Investors to Contact Law Firm
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
Analysts Conflicted on These Technology Names: Allscripts (MDRX), IsoPlexis (ISO) and Jack Henry & Associates (JKHY)
Fly Intel: After-Hours Movers
IsoPlexis Reports Lower Preliminary 2022 Revenue; Shares Down After-Hours
05:19 PM EST, 01/12/2023 (MT Newswires) -- IsoPlexis (ISO) said Thursday it expects full-year 2022 revenue of $16.6 million to $16.8 million, down from $17.3 million a year earlier. Three analysts sur
IsoPlexis Expects FY22 Revenue to Be Below Consensus
IsoPlexis: 4Q Results Were Lower Than Expected Primarily Due to the Timing of Customer Orders for Instruments and Lower Consumable Sales >ISO
IsoPlexis: 4Q Results Were Lower Than Expected Primarily Due to the Timing of Customer Orders for Instruments and Lower Consumable Sales >ISO
IsoPlexis Announces Preliminary Unaudited Revenue For The Full Year Ended Dec 31, 2022 Total Revenue To Be In The Range Of $16.6M-$16.8M, Down 3%-4% YoY; Q4 Results Were Lower Than Expected Primarily Due To The Timing Of Customer Orders For Instruments
IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full ye
IsoPlexis Sees 2022 Rev $16.6M-$16.8M >ISO
IsoPlexis Sees 2022 Rev $16.6M-$16.8M >ISO
Company Overview
More
IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. Its single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. The company was founded by Sean Mackay, Rong Fan, and Kara K. Brower in March 2013 and is headquartered in Branford, CT.
CEO： Mr. Sean Mackay
Market： NASDAQ
Listing Date： 10/08/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet